

Alameda Alliance for Health
1240 South Loop Road
Alameda, CA 94502

Location: Microsoft Teams
Meeting ID: 287 079 943 699
Password: oCYtiM

IMPORTANT PUBLIC HEALTH AND SAFETY MESSAGE REGARDING PARTICIPATION AT ALAMEDA ALLIANCE FOR HEALTH COMMITTEE MEETINGS

STATE OR LOCAL OFFICIALS CONTINUE TO IMPOSE OR RECOMMEND MEASURES TO PROMOTE SOCIAL DISTANCING. AS A RESULT OF THE COVID-19 VIRUS, AND RESULTING ORDERS AND DIRECTION FROM THE PRESIDENT OF THE UNITED STATES, THE GOVERNOR OF THE STATE OF CALIFORNIA, AND THE ALAMEDA COUNTY HEALTH OFFICER, THE PUBLIC WILL NOT BE PERMITTED TO PHYSICALLY ATTEND THE ALAMEDA ALLIANCE FOR HEALTH MEETING TO WHICH THIS AGENDA APPLIES.

YOU MAY SUBMIT COMMENTS ON ANY AGENDA ITEM OR ON ANY ITEM NOT ON THE AGENDA, IN WRITING VIA MAIL TO “ATTN: ALLIANCE PHARMACEUTICAL AND THERAPEUTICS COMMITTEE” 1240 SOUTH LOOP ROAD, ALAMEDA, CA 94502; OR THROUGH E-COMMENT AT bochoa@alamedaalliance.org YOU MAY WATCH THE MEETING LIVE BY LOGGING IN VIA COMPUTER AT THE FOLLOWING LINK: [Microsoft Teams Meeting](#) OR MAY LISTEN TO THE MEETING BY CALLING IN TO THE FOLLOWING TELEPHONE NUMBER: 1 510-210-0967. IF YOU USE THE LINK AND PARTICIPATE VIA COMPUTER, YOU MAY, THROUGH THE USE OF THE CHAT FUNCTION, REQUEST AN OPPORTUNITY TO SPEAK ON ANY AGENDIZED ITEM, INCLUDING GENERAL PUBLIC COMMENT. YOUR REQUEST TO SPEAK MUST BE RECEIVED BEFORE THE ITEM IS CALLED ON THE AGENDA. IF YOU PARTICIPATE BY TELEPHONE, YOU MAY SUBMIT ANY COMMENTS VIA THE E-COMMENT EMAIL ADDRESS DESCRIBED ABOVE OR PROVIDE COMMENT [DURING THE MEETING AT THE END OF EACH TOPIC](#).

PLEASE NOTE: THE ALAMEDA ALLIANCE FOR HEALTH IS MAKING EVERY EFFORT TO FOLLOW THE SPIRIT AND INTENT OF THE BROWN ACT AND OTHER APPLICABLE LAWS REGULATING THE CONDUCT OF PUBLIC MEETINGS, IN ORDER TO MAXIMIZE TRANSPARENCY AND PUBLIC ACCESS. DURING EACH AGENDA ITEM, YOU WILL BE PROVIDED A REASONABLE AMOUNT OF TIME TO PROVIDE PUBLIC COMMENT. THE COMMITTEE WOULD APPRECIATE, HOWEVER, IF COMMUNICATIONS OF PUBLIC COMMENTS RELATED TO ITEMS ON THE AGENDA, OR ITEMS NOT ON THE AGENDA, ARE PROVIDED PRIOR TO THE COMMENCEMENT OF THE MEETING.

AGENDA

ITEM VOTE	DESCRIPTION	TIME
I)	Call to order <i>Steve O'Brien, MD, Chief Medical Officer - Alameda Alliance</i> <ul style="list-style-type: none"> Agenda Overview 	2 min -
II)	Informational Updates <i>Steve O'Brien, MD, Chief Medical Officer - Alameda Alliance</i> <i>Helen Lee, PharmD MBA, Senior Pharmacy Director – Alameda Alliance</i> <ul style="list-style-type: none"> CalAIM Update (ECM, CS, LTC) Mental Health insourcing CEO transition Single plan county 2024 Medicare DHCS audit Medi-Cal Rx MCDAC Drugs (See next page) 	15 min -

MCDAC Drug	Indication	CDL Status	Recommendation Based on - Safety, Efficacy, Essential Need, Misuse Potential, etc.	Previous MCAL Status
Radicava (edaravone) ORS 105mg/5mL oral suspension	Amyotrophic lateral sclerosis (ALS)	F-PA	Keep F-PA	NF
Rexulti (brexiprazole) 0.25mg, 0.5mg, 1mg, 2mg, 3mg and 4mg tablets	Major depressive disorder (adjunct); Schizophrenia	F-PA	Keep F-PA	NF

III) Pharmacy Utilization Reports (Quarter 3, 2022)

Helen Lee, PharmD MBA, Senior Pharmacy Director – Alameda Alliance

- Top 50 Drugs by Cost
- Top 50 Requests by Volume

2
min

ADJOURN TO CLOSED SESSION (Pursuant to California Government Code Title 5, §54954.5(h))

Discussion will Concern: Review and Recommendations to changes to the AAH Formulary and utilization management for selected drug classes

Estimated Date of Public Disclosure: 12/20/2022 (formulary changes only; no trade secrets will be disclosed).

IV) E-Voting Material/Consent Agenda

The following items have been sent to the voting committee for review via E-voting

Helen Lee, PharmD MBA, Senior Pharmacy Director – Alameda Alliance

Benita Ochoa, CPhT, Lead Pharmacy Technician – Alameda Alliance

Rahel Negash, PharmD, Pharmacist – Alameda Alliance

(All matters listed on the Consent Calendar are to be approved with one motion unless a member of the P&T Committee removes an item for separate action. Any consent calendar item for which separate action is requested shall be heard as the next Agenda item in closed session.)

10
min EV

Monographs/Class Reviews	Changes
Botulinum toxins comparative review	• No change
COVID-19 tests (abbreviated) review	• No change
Impetigo agents class review	• No change
Methergine monograph	• No change
Pneumococcal vaccine comparative review	• No change
Prenatal vitamins (abbreviated) review	• No change
Urinary antispasmodics class review	• No change
Medication Request Guidelines	Changes
Botulinum Toxins A&B	• Add “divalproex ER or DR, valproic acid” in place of Depakote • Minor wording updates •
Urinary Incontinence Agents	• Remove sections regarding Oxytrol for women OTC as MCAL formulary option
Tetracycline Antibiotics	• Add “formulary, prior authorization required” tetracyclines language

Blood Glucose Testing Supplies	<ul style="list-style-type: none"> • Move sections to line up with the left-hand side of policy for clarity • Minor word changes for clarity
Endari	<ul style="list-style-type: none"> • Minor word changes for clarity
Fentanyl Citrate	<ul style="list-style-type: none"> • Minor word changes for clarity
Proton Pump Inhibitors (PPIs)	<ul style="list-style-type: none"> • Update brand/generic status of Dexilant
Injectable Methotrexate	<ul style="list-style-type: none"> • Modify calcipotriene requirement to be less prescriptive and inclusive of other vitamin D analogue drug class medications •
Testosterone Agents	<ul style="list-style-type: none"> • Add Tlando and Kyzatrex to list of non-preferred agents •
Thalomid (thalidomide)	<ul style="list-style-type: none"> • No change
Temazepam (Restoril)	<ul style="list-style-type: none"> • No change
Diclofenac sodium (Solaraze) 3% gel	<ul style="list-style-type: none"> • No change
Step Therapy Exception	<ul style="list-style-type: none"> • No change
Prior Authorization Exception	<ul style="list-style-type: none"> • No change
Rayaldee (calcifediol ER)	<ul style="list-style-type: none"> • No change
Korlym (mifepristone)	<ul style="list-style-type: none"> • No change
Oral Anti-Fungals	<ul style="list-style-type: none"> • No change
Gattex (teduglutide)	<ul style="list-style-type: none"> • No change
Physician Administered Drug (PAD) Guidelines	Changes
Healthcare professional (HCP) administered/IV Disease Modifying Therapies (DMTs) for Multiple Sclerosis (MS)	<ul style="list-style-type: none"> • Minor word changes for clarity
Tepezza	<ul style="list-style-type: none"> • Minor word changes for clarity
Botulinum Toxins A&B	<ul style="list-style-type: none"> • Minor word changes for clarity
Injectable/Specialty Medications	<ul style="list-style-type: none"> • Add in referral to the oncology policy for oncology medication requests
Oral and Injectable Oncology Medications	<ul style="list-style-type: none"> • Minor word changes for clarity • Add NCCN guidelines as an option for the dose appropriateness statement
Viltepsa	<ul style="list-style-type: none"> • No change
Interim Formulary Updates	
<ul style="list-style-type: none"> • See p. 121 in packet 	
Pharmacy Policy & Procedure Updates	
<ul style="list-style-type: none"> • No Updates 	
P&T Meeting Minutes	
<ul style="list-style-type: none"> • P&T Meeting Minutes Q3 September 20, 2022 	

90 Day Maintenance List Updates

- Yearly Review – No changes

ED Oversight

- Quarterly Review – No Changes

V) New Business

Natalee Felten, PharmD, Pharmacist, PerformRx

- Agents for graft versus host disease MRG - new
- Janus Kinase Inhibitors for Nonsegmental Vitiligo MRG – new
- Budesonide Nebulization Solution (Pulmicort Respules) - new
- Essential Health Benefits (EHB) Formulary Benchmark Analysis and Recommendations

VI) Class Reviews, Monographs, and Recommendations

Natalee Felten, PharmD, Pharmacist, PerformRx

1. Contraceptives (abbreviated) review
2. Multiple sclerosis class review
3. ICS/LABA Combinations class review
4. Inhaled Corticosteroids (ICS) class review
5. Topical medications for psoriasis class review

VII) Medication Request Guidelines

Rahel Negash, PharmD, Pharmacist, Alameda Alliance

45 min V

Review:

1. Hepatitis B Drugs
2. Growth Hormone
3. Isotretinoin capsules
4. Gonadotropin Releasing Hormone (GNRH) Agonists
5. Anti-Obesity Medications
6. Topical Diclofenac
7. Immunizations
8. Otezla (apremilast) for Behcet Disease
9. Ranolazine ER (Ranexa)
10. Butorphanol (Stadol NS)
11. Oral and Injectable Oncology Medications
12. Injectable/Specialty Medications
13. Brand Medications When a Generic or Biosimilar is Available

VIII) Physician Administered Drug (PAD) Policies

Natalee Felten, PharmD, Pharmacist, PerformRx

1. Neuromyelitis Optica Spectrum Disorder (NMOSD) Agents

10 min V

- IX) Informational Updates on New Developments in Pharmacy** 2 min
Natalee Felten, PharmD, Pharmacist, PerformRx
- New Product Review

- X) Old Business** 2 min
Natalee Felten, PharmD, Pharmacist, PerformRx
- None

RECONVENE IN OPEN SESSION

- XI) Public Comment**

- XII) Adjournment**
- P&T Committee Member Forms

ACTION / FOLLOW-UP ITEMS

ITEM	DUE DATE	RESPONSIBLE

FUTURE P&T MEETINGS

NEXT MEETING	2023 P&T MEETINGS
March 21st 2023	June 20 th 2023
	September 26 th 2023
	December 19 th 2023

The Alameda Alliance for Health Pharmacy & Therapeutics Committee welcomes you to its meetings and your interest is appreciated. If you wish to speak on a matter on the agenda, you will have the opportunity to do so in the order determined by the Chair. If you wish to speak on a matter not on the agenda, please wait until the Chair asks for public comments at the end of the regular agenda. Please be brief and limit your comments to the specific subject under discussion.

Note: Only matters within the jurisdiction of the Alameda Alliance for Health Pharmacy & Therapeutics Committee may be addressed. If necessary, the Chair may limit the total time to be devoted to public comment on any item, and the time allotted to individual speakers, to ensure sufficient time for the consideration of all matters on the agenda.

This meeting is wheelchair accessible. Please contact Helen Lee at 510-747- 6241 or hlee@alamedaalliance.org at least 72 hours before the meeting to request agenda materials in an alternative format, or any other reasonable disability-related accommodations or services that may be necessary for you to participate in and enjoy the benefits of the meeting.